Skip to main content

← All trials/NCT06818292

GLPsy

CompletedPhase NA

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

Lead sponsor

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

10

Study population

Healthy volunteers

Eligibility highlights

•BMI 18.5-25

Primary endpoints

•Neuropsychology•Neuropsychology (vlmt a score, block span score)•MR spectroscopy

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06818292

Org study ID2024-3513-BO

Timeline

Milestones

Study start2024-10-21actual

Primary completion2024-12-06actual

Study completion2024-12-06actual

Study first posted2025-02-10actual

Last update posted2025-02-10actual

Assets

Investigational agents

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years

Maximum age43 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Normal weight at study inclusion (BMI 18.5-25)

•Generally good physical condition without serious previous illnesses

Exclusion criteria

•MRI contraindication: cardiac pacemakers, hearing aids, neurostimulation, insulin pumps, other potentially ferromagnetic implants, screws, clips, prostheses, metal splinters, etc., pregnancy, claustrophobia, extensive tattoos, medication that impairs thermoregulation

•Comorbidity: neurological or psychiatric conditions, cognitive impairments, chronic somatic disorders

•Intake of more than 40g of pure alcohol (for men) or more than 20g of pure alcohol (for women), smoking, regular drug use

•Pregnancy or nursing

•Current or within the past five years eating disorder, vegan diet or fasting within the past six months

•Regular medication intake

•Liraglutide contraindications: Hypersensitivity to liraglutide or other components of the medication, medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia endocrine neoplasia syndrome type 2 (MEN2) in personal or family history, history of pancreatitis, current pregnancy or breastfeeding, severe gastrointestinal motility disorders including gastroparesis, severe or terminal renal insufficiency

Endpoints (21)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

8

Patient-reported / QoL

7

Other clinical outcomes

5

Cardiometabolic biomarkers

1

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Lipid profiling

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Patient-reported / QoL

7 endpoints

Secondary/protocol endpoint

Sleep

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

change from baseline, improvement

Secondary/protocol endpoint

Depression

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

change from baseline, improvement

Secondary/protocol endpoint

Anxiety

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Secondary/protocol endpoint

Anhedonia

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Secondary/protocol endpoint

Life quality

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Secondary/protocol endpoint

Numeric Analog Scales

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Secondary/protocol endpoint

Fatigue

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Other clinical outcomes

5 endpoints

Primary/protocol endpoint

Neuropsychology: Processing speed

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Primary/protocol endpoint

Neuropsychology: Attention

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Primary/protocol endpoint/low confidence

Neuropsychology: Memory

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

componentsvlmt a score, block span score

Primary/protocol endpoint

Neuropsychology: Verbal Fluency

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive, improvement

Secondary/protocol endpoint

Structural MR imaging

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Other (unclassified)

8 endpoints

Primary/protocol endpoint/low confidence

MR spectroscopy

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Primary/protocol endpoint/low confidence

Exploratory Proteomics of Autophagy Processes I

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Primary/protocol endpoint/low confidence

Exploratory Proteomics of Autophagy Processes II

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Secondary/protocol endpoint/low confidence

Functional MRI

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Secondary/protocol endpoint/low confidence

Metabolic processes

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Secondary/protocol endpoint

Transcription expression patterns

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Secondary/protocol endpoint/low confidence

Proteome/phosphoproteome/ubiquitinome patterns

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Secondary/protocol endpoint/low confidence

Exosomal protein patterns

Time frame:Outcome measures are assessed during a one-week on-site visit per participant (placebo vs. liraglutide days) within an overall study period of 2 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.